Abdominal Aortic Aneurysm Screening
Customize your policy alerts
Sign up for Aetna Policy 0702 alerts
Get alerted when Policy 0702 changes without checking for updates manually.
Monitor payer policy activity
Defines Aetna's medical necessity and experimental/investigational determinations for one-time ultrasound screening for abdominal aortic aneurysm (AAA), including CPT/HCPCS/ICD-10 codes referenced and background evidence summary. This part (1 of 2) includes policy statements, code lists, and extensive background literature review through AI applications.
No material clinical/coverage changes — has_material_change=false in the brief.
Coverage Summary & Scope
Scope: This policy defines Aetna’s determinations for screening for abdominal aortic aneurysm (AAA). It designates one-time ultrasound screening (CPT 76706) as medically necessary for men aged 65 to 75 years who have ever smoked, with selective offering to men in the same age range who have never smoked, and considers other screening indications not established.
Coverage stance: routine screening in women is not recommended by the USPSTF and is not supported as a population-based service; use of artificial intelligence (AI) or other expanded screening indications are considered experimental/investigational because effectiveness and external validation are not established.
Coverage and Medical Necessity Criteria
Medical Necessity
Covered when ALL of the following are met:
ALL of the following
- One-time ultrasound screening for abdominal aortic aneurysms (AAA) is medically necessary for men 65 years of age or older.
Experimental and Investigational - AAA screening
Not covered (considered experimental/investigational) when ANY of the following apply:
ANY of the following
- AAA screening for all indications other than one-time ultrasound screening for men 65 years of age or older.
Experimental and Investigational - Artificial Intelligence
Use of AI is considered experimental/investigational for AAA when used for any of the following:
ANY of the following
- Screening and identification of abdominal aortic aneurysm (AAA), including prediction of AAA growth and rupture.
- Pre-operative planning and sizing of endografts.
- Predicting post-operative outcomes, including mortality and complications following endovascular aneurysm repair.
Applicable Codes
| 76706 | Ultrasound, abdominal aorta, real time with image documentation, screening study for abdominal aortic aneurysm (AAA). |
| No specific CPT | Artificial intelligence for the screening and identification of Abdominal Arotic Aneurysm (AAA)- no specific code |
| F17.210 - F17.219 | Nicotine dependence, cigarettes. |
| Z13.6 | Encounter for screening for cardiovascular disorders [abdominal aortic aneurysm (AAA)]. |
| Z87.891 | Personal history of nicotine dependence. |
Prior Authorization, Documentation & Denial Risk
Prior authorization may be required for screening ultrasound
Report CPT 76706 (Ultrasound, abdominal aorta, screening study for AAA) only when the policy selection criteria are met (one-time screening for men 65–75 who have ever smoked). Other indications are not covered and prior authorization may be required.
- Affected code: 76706
Document smoking history
Document the patient’s nicotine/tobacco use status and ever‑smoker history in the medical record. Relevant ICD‑10 codes referenced by the policy include F17.210–F17.219 (nicotine dependence, cigarettes) and Z87.891 (personal history of nicotine dependence); this supports application of USPSTF guidance for screening benefit.
- ICD‑10: F17.210–F17.219
- ICD‑10: Z87.891
Claims for AI-based AAA screening tools risk denial
Claims for AI-based tools used for AAA screening, detection, prediction (including growth or rupture), pre‑operative planning/sizing of endografts, or predicting post‑operative outcomes are considered experimental and investigational and will be denied as not medically necessary.
Reference evidence and limitations for AI-based AAA detection
Evidence for AI applications in AAA is preliminary. Studies are often single‑center or retrospective, have sampling or selection bias, limited external validation, and methodological limitations. Performance may be reduced for small aneurysms (e.g., <3.3 cm) and in cases with mural thrombus; larger, multi‑center validation and transparent reporting are needed before routine clinical use.
- AI studies frequently single‑center or retrospective with limited sample sizes
- High study heterogeneity and sampling bias; many datasets lacked non‑pathologic controls
- Reported reduced AI performance for small aneurysms (e.g., <3.3 cm) and with mural thrombus
- External validation and standardized reporting are lacking
Background & Evidence Summary
The USPSTF and randomized screening trials provide the primary evidence supporting one-time ultrasonography screening in men aged 65 to 75 who have ever smoked, showing reduced AAA-related mortality when screening is coupled with appropriate surveillance and treatment.
The USPSTF found a moderate net benefit for that group, recommended selective offering for never-smokers, and recommended against routine screening in women because of low prevalence of clinically important AAAs and a poor balance of benefits versus harms.
Surveillance recommendations for screen-detected AAAs follow established diameter thresholds: small AAAs (3.0–3.9 cm) are monitored with periodic ultrasound, intermediate AAAs (4.0–5.4 cm) are followed more closely, and repair is generally considered at the 5.5 cm threshold; example surveillance intervals cited include repeat ultrasound every 6 months for AAAs >4 cm and every 2 years for smaller AAAs.
For post-EVAR surveillance and endoleak detection, pooled data show that color duplex ultrasound (unenhanced and enhanced) has lower sensitivity than CT angiography for endoleak detection (pooled sensitivity for unenhanced duplex ~66%, enhanced ~81%; specificity high for unenhanced ~93%).
Recent and emerging literature explores expanded screening criteria beyond USPSTF recommendations and multiple potential applications of AI for opportunistic detection, segmentation, and prediction; preliminary AI studies report high diagnostic metrics but are limited by single-center designs, sampling bias, limited external validation, and performance limits for small aneurysms.
Because of these limitations, AI applications for screening, operative planning, growth/rupture prediction, and outcome prediction are considered experimental pending further validation.
| Evidence source | Key finding |
|---|---|
| USPSTF recommendation | One-time screening with ultrasonography recommended for men 65–75 who have ever smoked (B); selectively offer to never-smokers (C); insufficient evidence for women who ever smoked (I); recommend against routine screening for women who never smoked (D). |
| Surgical mortality benefit | Open repair for AAA ≥5.5 cm associated with an estimated ~43% reduction in AAA-specific mortality in older men detected by screening. |
| Duplex US vs CTA (Sun 2006) | Pooled estimates: unenhanced color duplex US sensitivity 66%, specificity 93%; enhanced color duplex US sensitivity 81%, specificity 82%; authors concluded duplex US is less accurate than CT angiography and cannot replace CT for follow-up after EVAR. |
| Kodenko et al (2022) - systematic review | Included 8 studies (355 cases, 273 with AAA); mean sensitivity 95% (95% CI 87–100%), mean specificity 96.6% (95% CI 75.7–100%), mean accuracy 95.2% (95% CI 54.5–100%); high heterogeneity and bias due to patient selection; further balanced studies needed. |
| Camara et al (2022) - single-center CNN study | Retrospective single-center CTA study (200 AAA, 200 controls) reporting accuracy 99.1% and AUC 0.99; reduced performance for small aneurysms (<3.3 cm) with mural thrombus; limited by single-center design and sample size. |
| Lareyre et al (2023) - commentary | Acknowledged high preliminary performance of AI models but emphasized need for external validation, transparency (e.g., reporting accuracy before transfer learning), and further studies before clinical application. |
Key Definitions and Clinical Thresholds
One-time ultrasound screening: A single ultrasonographic examination of the abdominal aorta to detect an AAA; typically reported with CPT 76706 when performed as a screening study.
Ever smoker: Individuals who currently or formerly smoked (used by USPSTF to stratify screening benefit and guide offering of one-time screening).
Policy Revision History
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.